Anxiety during follow-up is described in a variety of cancers including prostate cancer.30 Scanxiety captures the particular distress reported by patients who are scheduled for surveillance and imaging to detect disease progression.31 The same phenomenon is described for prostate cancer survivors who experience physical or emotional distress around the time of PSA-testing.32 In addition, every PSA-test further diagnostic work-up and subsequent contact with a healthcare professional consume healthcare resources and it is important to balance risk and benefit with follow-up. This evidence concerns the gene KLK3 and cancer.